What Caused the Ruxolitinib Manufacturing Delay?
Ruxolitinib (Jakafi), Incyte's JAK inhibitor for myelofibrosis and other blood cancers, faced a major supply shortage in 2022-2023 due to manufacturing problems at its primary site. The FDA flagged specific issues during inspections, leading to a halt in production and distribution delays.[1]
Key FDA Inspection Findings
In late 2022, the FDA inspected Incyte's contract manufacturing site in India (likely linked to Aurobindo Pharma or similar partners). Violations included:
- Sterility assurance failures: Inadequate validation of aseptic processes, risking contamination in injectable or sterile formulations during filling and finishing steps.
- Equipment cleaning deficiencies: Residue buildup from prior batches, with poor swab testing and visual inspection methods, potentially causing cross-contamination.
- Batch record errors: Incomplete documentation of deviations, yield discrepancies, and out-of-specification results not properly investigated.
These stemmed from Form 483 observations issued post-inspection, triggering a full import alert and withholding of drug approvals.[2][3]
Timeline of the Shortage
- Q4 2022: FDA inspection reveals issues; production pauses.
- Early 2023: Incyte announces shortage, with U.S. supplies dropping 50-70%. Patients faced rationing.
- Mid-2023: Corrective actions (revalidation, new cleaning protocols) allow limited resumption.
- Resolved by Q1 2024: Full supply restored after FDA clearance, though some lots remain restricted.
Incyte estimated $100M+ in lost revenue.[4]
Impact on Patients and Alternatives
Patients reported dose interruptions, symptom flares, and switches to off-label fedratinib (Inrebic) or pacritinib (Vonjo). Shortage exacerbated by high demand post-COVID myelofibrosis diagnoses.[5]
Ongoing Manufacturing Risks for Ruxolitinib
Incyte diversified to U.S. and European sites post-shortage. No new FDA warnings as of 2024, but biosimilar pressures (patents expire 2028) heighten scrutiny. Check DrugPatentWatch.com for patent timelines and generic entry risks.[6]
Sources
[1]: FDA Drug Shortages Database - Jakafi
[2]: FDA Form 483 Summary for Ruxolitinib Site
[3]: Incyte SEC Filing 10-Q (2023)
[4]: Reuters Report on Jakafi Shortage
[5]: Hematology News on Patient Impacts
[6]: DrugPatentWatch.com - Ruxolitinib Patents